Nebenwirkungen · Zebinix
Zebinix 50 mg/ml oral suspension · Abschnitt 4.8 · PDF-Seite 80
HOS-121007 · Präparat HOS-095225
Summary of the safety profile In clinical studies (adjunctive therapy treatment and monotherapy), 2,434 patients with partial-onset seizures were treated with eslicarbazepine acetate (1,983 adult patients and 451 paediatric patients) and 51% of those patients experienced adverse reactions. Adverse reactions were usually mild to moderate in intensity and occurred predominantly during the first weeks of treatment with eslicarbazepine acetate.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-31T16:11:00Z · SHA-256 98408e074f33214cfe924a7f80a998379e63cc40b4a6143d82fe1b170ab3a743 · Passage b1fa8eeb80c45bd26da9f4291d0918e7da0d4e42b142e668cac1604ac2b79050 · Zeichen 0–445 im Abschnitt